Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (9)

2017

  1. A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice

    Neuropsychopharmacology, Vol. 42, Núm. 2, pp. 524-539

2016

  1. Pharmacokinetic investigation of sildenafil using positron emission tomography and determination of its effect on cerebrospinal fluid cGMP levels

    Journal of Neurochemistry, Vol. 136, Núm. 2, pp. 403-415

2015

  1. Concomitant histone deacetylase and phosphodiesterase 5 inhibition synergistically prevents the disruption in synaptic plasticity and it reverses cognitive impairment in a mouse model of Alzheimer’s disease

    Clinical Epigenetics, Vol. 7, Núm. 1

  2. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

    Neuropathology and Applied Neurobiology, Vol. 41, Núm. 4, pp. 471-482

2014

  1. Phosphodiesterase inhibition in cognitive decline

    Journal of Alzheimer's Disease, Vol. 42, pp. S561-S573

  2. Synthesis and evaluation of 13N-labelled azo compounds for β-amyloid imaging in mice

    Molecular Imaging and Biology, Vol. 16, Núm. 4, pp. 538-549

2013

  1. Epigenetic drugs in Alzheimer's disease

    Biomolecular Concepts, Vol. 4, Núm. 5, pp. 443-445

  2. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimeŕs disease-like phenotype of a commonly used mouse model

    Current Pharmaceutical Design, Vol. 19, Núm. 28, pp. 5076-5084

  3. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD

    Neuropharmacology, Vol. 64, pp. 114-123